These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 29982758)

  • 1. What's Next for Patient-Derived Xenograft Modeling?
    Gritters J
    J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 29982758
    [No Abstract]   [Full Text] [Related]  

  • 2. Moving ahead with personalized mouse models.
    Bender E
    Cancer Discov; 2013 Nov; 3(11):1214. PubMed ID: 24203942
    [No Abstract]   [Full Text] [Related]  

  • 3. Patient-derived tumor xenograft models in drug development.
    Hidalgo M
    Clin Adv Hematol Oncol; 2017 Nov; 15(11):844-846. PubMed ID: 29200416
    [No Abstract]   [Full Text] [Related]  

  • 4. Zebrafish Xenografts for Drug Discovery and Personalized Medicine.
    Xiao J; Glasgow E; Agarwal S
    Trends Cancer; 2020 Jul; 6(7):569-579. PubMed ID: 32312681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments.
    Zarzosa P; Navarro N; Giralt I; Molist C; Almazán-Moga A; Vidal I; Soriano A; Segura MF; Hladun R; Villanueva A; Gallego S; Roma J
    Clin Transl Oncol; 2017 Jan; 19(1):44-50. PubMed ID: 27718156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Building avatar armies with fish and flies.
    Neff EP
    Lab Anim (NY); 2020 Apr; 49(4):101-104. PubMed ID: 32210417
    [No Abstract]   [Full Text] [Related]  

  • 7. Novartis Compiles Mouse Avatar "Encyclopedia".
    Poh A
    Cancer Discov; 2016 Jan; 6(1):5-6. PubMed ID: 26621761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients.
    Rubio-Viqueira B; Hidalgo M
    Clin Pharmacol Ther; 2009 Feb; 85(2):217-21. PubMed ID: 19005462
    [No Abstract]   [Full Text] [Related]  

  • 9. Testing PARP Inhibitors Using a Murine Xenograft Model.
    Makhov P; Naito S; Kolenko VM
    Methods Mol Biol; 2017; 1608():313-320. PubMed ID: 28695518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. US cancer institute to overhaul tumour cell lines.
    Ledford H
    Nature; 2016 Feb; 530(7591):391. PubMed ID: 26911756
    [No Abstract]   [Full Text] [Related]  

  • 11. A PET rat model for assessing the effectiveness of new chemotherapies.
    Winnard PT; Sukumar S
    Cancer Biol Ther; 2008 Apr; 7(4):538-9. PubMed ID: 18627116
    [No Abstract]   [Full Text] [Related]  

  • 12. Lessons from patient-derived xenografts for better in vitro modeling of human cancer.
    Choi SY; Lin D; Gout PW; Collins CC; Xu Y; Wang Y
    Adv Drug Deliv Rev; 2014 Dec; 79-80():222-37. PubMed ID: 25305336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer: Xenograft encyclopaedia identifies drug combination opportunities.
    Cully M
    Nat Rev Drug Discov; 2015 Dec; 14(12):818. PubMed ID: 26585532
    [No Abstract]   [Full Text] [Related]  

  • 14. A novel zebrafish human tumor xenograft model validated for anti-cancer drug screening.
    Jung DW; Oh ES; Park SH; Chang YT; Kim CH; Choi SY; Williams DR
    Mol Biosyst; 2012 Jul; 8(7):1930-9. PubMed ID: 22569777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics and pharmacogenomics as tools in cancer therapy.
    Rodríguez-Vicente AE; Lumbreras E; Hernández JM; Martín M; Calles A; Otín CL; Algarra SM; Páez D; Taron M
    Drug Metab Pers Ther; 2016 Mar; 31(1):25-34. PubMed ID: 26863347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-derived tumour models for personalized therapeutics in urological cancers.
    van de Merbel AF; van der Horst G; van der Pluijm G
    Nat Rev Urol; 2021 Jan; 18(1):33-45. PubMed ID: 33173206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status and future outlook for patient-derived cancer models from a rare cancer research perspective.
    Kondo T
    Cancer Sci; 2021 Mar; 112(3):953-961. PubMed ID: 32986888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More Than One Way to Measure? A Casuistic Approach to Cancer Clinical Trials.
    Andreoletti M
    Perspect Biol Med; 2018; 61(2):174-190. PubMed ID: 30146517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-derived cell models as preclinical tools for genome-directed targeted therapy.
    Lee JY; Kim SY; Park C; Kim NK; Jang J; Park K; Yi JH; Hong M; Ahn T; Rath O; Schueler J; Kim ST; Do IG; Lee S; Park SH; Ji YI; Kim D; Park JO; Park YS; Kang WK; Kim KM; Park WY; Lim HY; Lee J
    Oncotarget; 2015 Sep; 6(28):25619-30. PubMed ID: 26296973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Significance of Mouse Models in Lymphoma Research.
    Noble JN; Mishra A
    Curr Hematol Malig Rep; 2019 Apr; 14(2):119-126. PubMed ID: 30848424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.